Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionNucleoside reverse transcriptase inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat hepatitis B virus (HBV) infections
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today